Drug Profile
Research programme: anti-infectives - Bristol-Myers Squibb
Alternative Names: Antibacterials research programme - Bristol-Myers Squibb; Antifungals research programme - Bristol-Myers Squibb; BMS 249524; BMS 411886; BMS 461996; Isoxazolinone antibacterials research programme - Bristol-Myers Squibb; Nocathiacin ILatest Information Update: 15 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Isoxazoles; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
- 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals
- 09 May 2001 Preclinical development for Bacterial infections in USA (Unknown route)